Your browser doesn't support javascript.
loading
Synthesis of deuterium-labeled CCR2 antagonist JNJ-26131300, [4-(1H-indol- 3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid.
Lin, Ronghui; Gong, Yong; Salter, Rhys.
Afiliação
  • Lin R; Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Gong Y; Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Salter R; Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.
J Labelled Comp Radiopharm ; 65(5): 147-151, 2022 05 15.
Article em En | MEDLINE | ID: mdl-35218060
ABSTRACT
Synthesis of multiple deuterium-labeled CCR2 antagonist JNJ-26131300, that is, [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid, is described. First, condensation of indole-D7 with 4-piperidone produced 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-D5 , which subsequently underwent catalytic hydrogenation to give 3-piperidin-4-yl-1H-indole-D5 . Next, bromo-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid was prepared through multiple steps from 3-(3,4,5-trifluoro-phenyl)-acrylic acid and bromo-piperidin-4-yl-acetic acid ethyl ester. Nucleophilic coupling of 3-piperidin-4-yl-1H-indole-D5 with bromo-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid afforded the desired compound [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid-D5 .
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Acético / Indóis Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Acético / Indóis Idioma: En Ano de publicação: 2022 Tipo de documento: Article